14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.91 $2.71 Tuesday, 23rd Apr 2024 CANF stock ended at $1.97. This is 0.505% less than the trading day before Monday, 22nd Apr 2024. During the day the stock fluctuated 0.81% from a day low at $1.96 to a day high of $1.98.
90 days $1.91 $2.71
52 weeks $1.71 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Dec 01, 2021 $1.18 $1.21 $1.08 $1.09 188 816
Nov 30, 2021 $1.16 $1.20 $1.12 $1.20 150 212
Nov 29, 2021 $1.21 $1.22 $1.14 $1.18 190 093
Nov 26, 2021 $1.20 $1.25 $1.17 $1.23 162 123
Nov 24, 2021 $1.20 $1.24 $1.18 $1.22 98 449
Nov 23, 2021 $1.21 $1.22 $1.17 $1.19 232 350
Nov 22, 2021 $1.24 $1.24 $1.16 $1.19 245 639
Nov 19, 2021 $1.25 $1.25 $1.19 $1.21 229 547
Nov 18, 2021 $1.31 $1.33 $1.20 $1.23 297 564
Nov 17, 2021 $1.37 $1.37 $1.26 $1.32 223 523
Nov 16, 2021 $1.36 $1.38 $1.30 $1.32 279 980
Nov 15, 2021 $1.35 $1.52 $1.32 $1.35 1 550 951
Nov 12, 2021 $1.39 $1.41 $1.30 $1.34 467 305
Nov 11, 2021 $1.44 $1.45 $1.35 $1.40 297 287
Nov 10, 2021 $1.47 $1.47 $1.40 $1.42 162 314
Nov 09, 2021 $1.48 $1.49 $1.44 $1.47 127 375
Nov 08, 2021 $1.49 $1.50 $1.48 $1.49 132 953
Nov 05, 2021 $1.50 $1.52 $1.46 $1.49 127 403
Nov 04, 2021 $1.51 $1.56 $1.48 $1.52 186 951
Nov 03, 2021 $1.50 $1.54 $1.48 $1.49 164 237
Nov 02, 2021 $1.48 $1.57 $1.47 $1.51 521 582
Nov 01, 2021 $1.55 $1.55 $1.47 $1.51 248 515
Oct 29, 2021 $1.52 $1.55 $1.50 $1.52 87 634
Oct 28, 2021 $1.59 $1.60 $1.49 $1.50 258 679
Oct 27, 2021 $1.50 $1.63 $1.49 $1.55 613 946
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT